MX2017011851A - Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. - Google Patents
Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso.Info
- Publication number
- MX2017011851A MX2017011851A MX2017011851A MX2017011851A MX2017011851A MX 2017011851 A MX2017011851 A MX 2017011851A MX 2017011851 A MX2017011851 A MX 2017011851A MX 2017011851 A MX2017011851 A MX 2017011851A MX 2017011851 A MX2017011851 A MX 2017011851A
- Authority
- MX
- Mexico
- Prior art keywords
- riboside
- nicotinamide
- nar
- derivatives
- tissues
- Prior art date
Links
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 235000020956 nicotinamide riboside Nutrition 0.000 title abstract 3
- 239000011618 nicotinamide riboside Substances 0.000 title abstract 3
- PUEDDPCUCPRQNY-ZYUZMQFOSA-N D-ribosylnicotinate Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CC(C([O-])=O)=C1 PUEDDPCUCPRQNY-ZYUZMQFOSA-N 0.000 title 1
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 1- (2 ' Chemical compound 0.000 abstract 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000037041 intracellular level Effects 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000008223 ribosides Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Genetics & Genomics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Artificial Fish Reefs (AREA)
Abstract
Se proporcionan derivados de ácido nicotínico ribósido (NAR), nicotinamida ribósido (NR) , y NAR y NR reducidos, incluyendo ácido 1- (2',3',Y-triacetil-beta-D-ribofuranosil)- 1,4-dihidronicotinico (4a), y composiciones que los contienen, y/o formas de derivados reducidos de nicotinamida ribósido, incluyendo 1-(2',3',5'-triacetil-beta-D-ribofuranosil)-1,4- nicotinamida (2), para use en el cuidado del tratamiento de la piel y afecciones de la piel. En algunas realizaciones, la invención se refiere a composiciones farmacéuticas y a composiciones cosméticas que contienen uno o más derivados de NR, NAR, NRH, o NARH, o profármacos o sales de los mismos. En realizaciones adicionales, la invención se refiere a métodos para usar uno o más derivados de NR, NAR, NRH, o NARH, o profármacos, solvatos, o sales de los mismos, para promover el incremento de niveles intracelulares de nicotinamida adenina dinucleótido (NAD+) en células y tejidos para mejorar la supervivencia de células y tejidos y la salud general de células y tejidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562133845P | 2015-03-16 | 2015-03-16 | |
| PCT/US2016/022682 WO2016149395A1 (en) | 2015-03-16 | 2016-03-16 | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017011851A true MX2017011851A (es) | 2018-04-11 |
| MX390185B MX390185B (es) | 2025-03-20 |
Family
ID=56920324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011851A MX390185B (es) | 2015-03-16 | 2016-03-16 | Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10280190B2 (es) |
| EP (1) | EP3271370B1 (es) |
| JP (2) | JP7244163B2 (es) |
| KR (1) | KR102426320B1 (es) |
| CN (2) | CN107531738B (es) |
| AU (1) | AU2016233247B2 (es) |
| BR (1) | BR112017019696A2 (es) |
| CA (1) | CA2979057C (es) |
| MX (1) | MX390185B (es) |
| NZ (1) | NZ735411A (es) |
| WO (1) | WO2016149395A1 (es) |
| ZA (1) | ZA201706918B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018517774A (ja) | 2015-06-10 | 2018-07-05 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 |
| EP3322419B1 (en) | 2015-07-15 | 2025-09-03 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| ES2948968T3 (es) * | 2016-04-20 | 2023-09-22 | Chromadex Inc | Uso del ribósido de ácido nicotínico o derivados del ribósido de nicotinamida, y derivados reducidos de los mismos, como precursores que aumentan el NAD++ |
| GB2553001A (en) * | 2016-08-19 | 2018-02-21 | The Queen's Univ Of Belfast | Lactone intermediates of nicotinamide riboside and nicotinate riboside |
| CN120463761A (zh) | 2016-11-11 | 2025-08-12 | 英国贝尔法斯特女王大学 | 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、磷酸化的类似物、腺苷二核苷酸共轭物、以及新颖结晶形式的有效且可规模化的合成 |
| MX2019006278A (es) | 2016-11-29 | 2019-08-21 | Univ Iowa Res Found | Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia. |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| WO2018236814A2 (en) | 2017-06-19 | 2018-12-27 | Gangadhara Ganapati | NICOTINAMIDE RIBOSID DERIVATIVES AND USES THEREOF |
| CN110283221A (zh) * | 2018-03-19 | 2019-09-27 | 药源药物化学（上海）有限公司 | 杂环化合物的制备和纯化方法 |
| US10654883B2 (en) * | 2018-05-15 | 2020-05-19 | Jumpstart Fertility Pty Ltd | Inorganic salts of nicotinic acid mononucleotide as anti-aging agents |
| CN112135833A (zh) | 2018-05-18 | 2020-12-25 | 弗·哈夫曼-拉罗切有限公司 | (硫代)烟酰胺呋喃核糖苷盐及其组合物、制备方法和用途 |
| US20210196742A1 (en) * | 2018-05-22 | 2021-07-01 | Jumpstart Fertility Pty Ltd | Amino acid salts of nicotinic acid ribosides as anti-aging agents |
| JP2022512126A (ja) * | 2018-12-10 | 2022-02-02 | クロマデックス，インコーポレイテッド | ニコチノイルリボシド及びその誘導体の結晶形態、並びにその調製方法 |
| US11833167B2 (en) | 2018-12-17 | 2023-12-05 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| WO2020190703A1 (en) * | 2019-03-21 | 2020-09-24 | Elysium Health, Inc. | Methods for wound treatment |
| US20220125814A1 (en) * | 2019-03-21 | 2022-04-28 | Fred Hutchinson Cancer Research Center | Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor |
| JP7610531B2 (ja) * | 2019-06-05 | 2025-01-08 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 腎疾患を治療又は予防するための還元型ニコチンアミドリボシド |
| EP4471042A3 (en) | 2019-07-19 | 2025-03-05 | Biosynth AG | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof |
| KR102315139B1 (ko) * | 2019-12-17 | 2021-10-20 | 주식회사 휴메딕스 | 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체 |
| US20230095103A1 (en) * | 2020-03-09 | 2023-03-30 | Societe Des Produits Nestle S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of lung diseases and conditions |
| CN111909229B (zh) * | 2020-08-12 | 2023-05-05 | 福建瑞博奥科技有限公司 | 一种β-烟酰胺核糖氯化物的制备方法 |
| BR112023003217A2 (pt) * | 2020-09-15 | 2023-03-28 | Nestle Sa | Métodos para produzir ribosídeo de di-hidronicotinamida a partir do cloreto de ribosídeo de nicotinamida |
| WO2022157173A1 (en) * | 2021-01-19 | 2022-07-28 | Biosynth Ag | Method of making nicotinamide ribofuranoside salts by salt metathesis, the crystalline form of its tosylate salt and the co-crystallized form of its chloride:iodide salt |
| GB202107957D0 (en) * | 2021-06-03 | 2021-07-21 | Mitocholine Ltd | Nutritional compositions for skeletal muscle |
| CN115232184B (zh) * | 2021-12-06 | 2024-07-05 | 宁波熙健医药科技有限公司 | 呋喃核糖基吡啶衍生物及其药物组合物和用途 |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
| AU2023236547A1 (en) * | 2022-03-15 | 2024-08-22 | ChromaDex Inc. | Methods of producing crystalline beta nicotinamide riboside triacetate chloride |
| WO2024050120A2 (en) * | 2022-09-02 | 2024-03-07 | The Regents Of The University Of California | Nicotinamide-riboside and pterostilbene combinations to treat osteoarthritis |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| AU2024304543A1 (en) * | 2023-06-14 | 2026-01-15 | ChromaDex Inc. | Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5517960A (en) | 1991-10-18 | 1996-05-21 | Whang; Dong I. | Rotating internal combustion engine |
| AU681337B2 (en) * | 1991-10-23 | 1997-08-28 | Cancer Research Campaign Technology Limited | Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form |
| GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| WO2005077091A2 (en) * | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
| US7776326B2 (en) | 2004-06-04 | 2010-08-17 | Washington University | Methods and compositions for treating neuropathies |
| CA2610854A1 (en) * | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| CN101360421B (zh) * | 2005-11-18 | 2014-06-18 | 康乃尔研究基金会有限公司 | 烟酰核苷组合物及其使用方法 |
| CN105228627B (zh) | 2013-03-15 | 2018-07-13 | 纽斯尔特科学公司 | 亮氨酸和烟酸降低脂质水平 |
| GB201313465D0 (en) * | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| KR20220098049A (ko) * | 2013-10-30 | 2022-07-08 | 크로마덱스 아이엔씨. | 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물 |
| MX2016016071A (es) * | 2014-06-06 | 2017-07-11 | Glaxosmithkline Intellectual Property (No 2) Ltd | Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos. |
| US20160317420A1 (en) * | 2015-05-01 | 2016-11-03 | The Procter & Gamble Company | Method of improving the appearance of skin and compositions therefor |
| EP3322419B1 (en) | 2015-07-15 | 2025-09-03 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
-
2016
- 2016-03-16 US US15/072,121 patent/US10280190B2/en active Active
- 2016-03-16 AU AU2016233247A patent/AU2016233247B2/en active Active
- 2016-03-16 EP EP16765675.0A patent/EP3271370B1/en active Active
- 2016-03-16 WO PCT/US2016/022682 patent/WO2016149395A1/en not_active Ceased
- 2016-03-16 CA CA2979057A patent/CA2979057C/en active Active
- 2016-03-16 MX MX2017011851A patent/MX390185B/es unknown
- 2016-03-16 NZ NZ735411A patent/NZ735411A/en unknown
- 2016-03-16 BR BR112017019696A patent/BR112017019696A2/pt not_active Application Discontinuation
- 2016-03-16 JP JP2017548461A patent/JP7244163B2/ja active Active
- 2016-03-16 CN CN201680022370.2A patent/CN107531738B/zh active Active
- 2016-03-16 CN CN202010541644.7A patent/CN111643512A/zh active Pending
- 2016-03-16 KR KR1020177029466A patent/KR102426320B1/ko active Active
-
2017
- 2017-10-12 ZA ZA2017/06918A patent/ZA201706918B/en unknown
-
2020
- 2020-10-22 JP JP2020177461A patent/JP2021020934A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102426320B1 (ko) | 2022-07-29 |
| EP3271370A4 (en) | 2018-11-21 |
| HK1248240A1 (zh) | 2018-10-12 |
| WO2016149395A1 (en) | 2016-09-22 |
| JP2018508543A (ja) | 2018-03-29 |
| EP3271370B1 (en) | 2023-06-21 |
| CN107531738B (zh) | 2021-02-19 |
| CN107531738A (zh) | 2018-01-02 |
| AU2016233247B2 (en) | 2020-12-03 |
| US10280190B2 (en) | 2019-05-07 |
| BR112017019696A2 (pt) | 2018-09-04 |
| CA2979057A1 (en) | 2016-09-22 |
| CN111643512A (zh) | 2020-09-11 |
| EP3271370C0 (en) | 2023-06-21 |
| AU2016233247A1 (en) | 2017-09-21 |
| US20160272668A1 (en) | 2016-09-22 |
| JP2021020934A (ja) | 2021-02-18 |
| MX390185B (es) | 2025-03-20 |
| CA2979057C (en) | 2023-01-24 |
| KR20180004113A (ko) | 2018-01-10 |
| ZA201706918B (en) | 2019-01-30 |
| EP3271370A1 (en) | 2018-01-24 |
| NZ735411A (en) | 2021-07-30 |
| JP7244163B2 (ja) | 2023-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011851A (es) | Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. | |
| MX2018012849A (es) | Uso de derivados de ribósido de ácido nocotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores de que incementan nad+. | |
| MX2018001363A (es) | Derivados del mononucleotido de nicotinamida y sus usos. | |
| MX2016005574A (es) | Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. | |
| CL2020002055A1 (es) | Macrociclos como moduladores del regulador de conductncia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| AR081628A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| CO2017005790A2 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| MX2017016344A (es) | Compuestos de benzoxacepina oxazolidinona y metodos de uso. | |
| ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| MX376835B (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| UY35419A (es) | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina | |
| CL2020000019A1 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso. | |
| UY32387A (es) | Ciclopentanodionas herbicidamente activas, derivados, procesos para su preparación, composiciones que las comprenden y usos de las mismas | |
| UY37160A (es) | COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 | |
| MX2017000183A (es) | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. | |
| UY36416A (es) | 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de la mieloperoxidasa | |
| SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| DOP2010000342A (es) | Compuestos conteniendo nitrogeno triciclico y sus usos como antibacteriales | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| MX2019002615A (es) | Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion. | |
| CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer |